A five-day course of #ivermectin & #doxycycline for the treatment of #COVID19 may reduce the duration of illness – #PubMed

https://pubmed.ncbi.nlm.nih.gov/33278625/

Skip to main page content
COVID-19 Information

Public health information (CDC)

Research information (NIH)

SARS-CoV-2 data (NCBI)

Prevention and treatment information (HHS)

Español


NIH NLM LogoLog in

Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced
Full text links

Abstract
Randomized Controlled Trial
A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness
Sabeena Ahmed et al. Int J Infect Dis. 2021 Feb.
Free PMC article
Show details

Full text links
Cite

Abstract
Ivermectin, a US Food and Drug Administration-approved anti-parasitic agent, was found to inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication in vitro. A randomized, double-blind, placebo-controlled trial was conducted to determine the rapidity of viral clearance and safety of ivermectin among adult SARS-CoV-2 patients. The trial included 72 hospitalized patients in Dhaka, Bangladesh, who were assigned to one of three groups: oral ivermectin alone (12 mg once daily for 5 days), oral ivermectin in combination with doxycycline (12 mg ivermectin single dose and 200 mg doxycycline on day 1, followed by 100 mg every 12 h for the next 4 days), and a placebo control group. Clinical symptoms of fever, cough, and sore throat were comparable among the three groups. Virological clearance was earlier in the 5-day ivermectin treatment arm when compared to the placebo group (9.7 days vs 12.7 days; p = 0.02), but this was not the case for the ivermectin + doxycycline arm (11.5 days; p = 0.27). There were no severe adverse drug events recorded in the study. A 5-day course of ivermectin was found to be safe and effective in treating adult patients with mild COVID-19. Larger trials will be needed to confirm these preliminary findings.

Keywords: Bangladesh; COVID-19; Doxycycline; Ivermectin; SARS-CoV-2.

Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.

Conflict of interest statement
The authors declare that there are no known competing financial interests or personal relationships that could have appeared to influence the work described in this paper.

Figures
Figure 1
Figure 1 Cumulative viral recovery estimates in…
Comment in
Antiviral Effects of Ivermectin in COVID-19- Clinically Plausible?
Shukla DAK, et al. Int J Infect Dis. 2021. PMID: 34175482 Free PMC article. No abstract available.
Similar articles
Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial.
Vallejos J, et al. Trials. 2020. PMID: 33234158 Free PMC article. Clinical Trial.
The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
Chaccour C, et al. Trials. 2020. PMID: 32513289 Free PMC article.
Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A, et al. Trials. 2020. PMID: 33115543 Free PMC article.
Potential use of ivermectin for the treatment and prophylaxis of SARS-CoV-2 infection.
Cobos-Campos R, et al. Curr Res Transl Med. 2021. PMID: 34418758 Free PMC article. Review.
Ivermectin: an award-winning drug with expected antiviral activity against COVID-19.
Formiga FR, et al. J Control Release. 2021. PMID: 33038449 Free PMC article. Review.
See all similar articles
Cited by 59 articles
Efficacy of antiviral therapies for COVID-19: a systematic review of randomized controlled trials.
Vegivinti CTR, et al. BMC Infect Dis. 2022. PMID: 35100985 Free PMC article.
Ivermectin Should Not Be Recommended to Treat Severe Acute Respiratory Syndrome 2 Infection.
Boven AG, et al. Open Forum Infect Dis. 2021. PMID: 34984211 Free PMC article. No abstract available.
Chemoprophylaxis against COVID-19 among health-care workers using Ivermectin in low- and middle-income countries: A systematic review and meta-analysis.
Azeez TA, et al. Indian J Pharmacol. 2021. PMID: 34975139 Free PMC article.
A Case Report: Genetically Distinct Severe Acute Respiratory Syndrome Coronavirus-2 Variant Causing Reinfection.
Hossain ME, et al. Front Microbiol. 2021. PMID: 34956160 Free PMC article.
Bias as a source of inconsistency in ivermectin trials for COVID-19: A systematic review. Ivermectin’s suggested benefits are mainly based on potentially biased results.
Izcovich A, et al. J Clin Epidemiol. 2021. PMID: 34933115 Free PMC article.
See all “Cited by” articles
References
Alam M.T., Murshed R., Bhiuyan E., Saber S., Alam R., Robin R. A Case Series of 100 COVID-19 Positive Patients Treated with Combination of Ivermectin and Doxycycline. J Bangladesh Coll Physic Surg. 2020;38:10–15. doi: 10.3329/jbcps.v38i0.47512. – DOI
Caly L., Druce J.D., Catton M.G., Jans D.A., Wagstaff K.M. 2020. “The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res, from https://www.ncbi.nlm.nih.gov/pubmed/32251768 (Caly et al. 2020), Apr 3. – PMC – PubMed
Centers for Disease Control and Prevention . 2020. Interim Clinical Guidance for Management of Patients with Confirmed 2019 Novel Coronavirus (2019-nCoV) Infection, Updated March 7, 2020. [Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-manageme… [accessed 17.11.2020]
Chiu S.H., Lu A.Y. Metabolism and tissue residues. In: Campbell W.C., editor. Ivermectin and Abamectin. Springer-Verlag; New York, NY: 1989. pp. 131–143.
Johns Hopkins University of Medicine COVID-19 . 2020. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University.https://coronavirus.jhu.edu/map.html (accessed 17.11.2020)
Show all 8 references
Publication types
Randomized Controlled Trial
MeSH terms
Adult
COVID-19 / drug therapy*
COVID-19 / virology
Double-Blind Method
Female
Humans
Ivermectin / adverse effects
Ivermectin / therapeutic use*
Male
Middle Aged
SARS-CoV-2*
Substances
Ivermectin
Supplementary concepts
COVID-19 drug treatment
Related information
Cited in Books
MedGen
PubChem Compound (MeSH Keyword)
LinkOut – more resources
Full Text Sources
ClinicalKey
Elsevier Science
Europe PubMed Central
PubMed Central
Other Literature Sources
scite Smart Citations
Medical
ClinicalTrials.gov
MedlinePlus Health Information
Miscellaneous
NCI CPTAC Assay Portal
NCBI Literature Resources

MeSH PMC Bookshelf Disclaimer

FOLLOW NCBI
Connect with NLM


National Library of Medicine
8600 Rockville Pike
Bethesda, MD 20894

Web Policies
FOIA

Help
Accessibility
Careers

NLM
NIH
HHS
USA.gov